February 14, 2022 01:56 PM ESTUpdated 03:23 PM
Pharma

J&J de­fends talc bank­rupt­cy gam­bit as plain­tiffs mass in le­gal show­down

Nicole DeFeudis

Editor

Un­der a moun­tain of law­suits al­leg­ing its talc-based prod­ucts caused can­cer, J&J at­tempt­ed to dig it­self out by spin­ning the li­a­bil­i­ties in­to a sep­a­rate com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

A service from the Financial Times